Company Profile
Founded in 1996 by Dr. FX. Bernard & Dr. A. Deguercy, BIOalternatives is a private company (Contract Research Organization) specialized in Cellular and Molecular Pharmacology. BIOalternatives provides services to support early stages of drug discovery and claim substantiation of healthcare compounds using up-to-date in vitro technologies.
BIOalternatives develops and manages informative cell-based assays allowing faster and cost-effective selection of your compounds, our capabilities include:
- in vitro model development
- Development & management of cell-based assays,
- Development of optimized/multiplex analysis systems,
- Miniaturization/automation of assays,
- Primary and secondary screening (including High Content Screening) for hit to lead identification,
- Profiling, mechanism of action studies; proof-of-concept evidencing...
- Running of in vitro safety and toxicity assays.
BIOalternatives has a special expertise in:
- Epithelial cell and tissue models,
- Neural cell and tissue models,
- Mesenchymal cell and tissue models,
- Blood-derived immuno-inflammatory cells.
With 14 years of experience and more than 600 in vitro assays already developed, BIOalternatives provides services and customized solutions to more than 200 companies including the world's top pharmaceutical, nutraceutical and dermo-cosmetic industries.
Company Facts
Founded in 1996
Employees: 32 (28 scientists)
Corporate Headquarters: Gençay, Vienne France
Independent company (no financial/industrial investor)
700 square meter laboratory
600+ in vitro developed assays
Cumulative R&D spent: > 15 % of turnover
Research tax credit (CIR) accreditation (Europe)
Location
BIOalternatives is located in the Middle West of France; only 1.5 hour from Paris and Bordeaux by train and few minutes from the University of Poitiers.
